ASCENT: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
home / between-the-lines / ascent-sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer
Expert oncologists Aditya Bardia, MD, MPH, and Alison Conlin, MD, review clinical data behind the use of sacituzumab govitecan in metastatic TNBC from the phase 3 ASCENT study.